» Articles » PMID: 18774496

Minichromosome Maintenance Protein 2 is a Reliable Proliferative Marker in Breast Carcinoma

Overview
Specialty Pathology
Date 2008 Sep 9
PMID 18774496
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

This is a study aimed to examine the distribution pattern of a specific minichromosome maintenance protein 2 (MCM2) in benign and malignant breast tissue. We also aim to correlate the frequency of expression of MCM2 with the degree of tumor differentiation. We used immunohistochemistry to examine the distribution and expression pattern of MCM2 on formalin-fixed paraffin-embedded tissue sections of benign (n = 30) and malignant breast tissue (n = 70) (IDC 56, DCIS 4, ILC 2, nonductal 4, mixed type 4). We quantified MCM2 expression by calculating a labeling index, which represents the percentage of epithelial nuclei that stained positively. Immunoreactivity was heterogenous in all the 70 malignant cases examined. Epithelial cells in cycle are most frequent at the tumor periphery. Labeling index of MCM2 was greatest in grade 3 (poorly differentiated) and lowest in grade 1 tumors (well differentiated). Minichromosome maintenance protein 2 expression in breast cancer showed a positive association with histologic grade (P < .05). In all the benign breast tissue examined, no proliferating compartments could be characterized. Minichromosome maintenance protein 2 is a useful proliferative marker of breast carcinoma. The frequency of expression of MCM2 showed an inverse correlation with the degree of tumor differentiation.

Citing Articles

is critical to maintain the cell survival and self-renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway.

Li S, Liu H, Liu W, Shi N, Zhao M, Wanggou S Int J Biol Sci. 2023; 19(3):916-935.

PMID: 36778110 PMC: 9909993. DOI: 10.7150/ijbs.79095.


The Correlation between Proliferative Immunohistochemical Markers and Papillary Thyroid Carcinoma Aggressiveness.

Sheikh-Ahmad M, Shalata Y, Bejar J, Kreizman Shefer H, Sirhan M, Laniado M Medicina (Kaunas). 2023; 59(1).

PMID: 36676734 PMC: 9862399. DOI: 10.3390/medicina59010110.


MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Yousef E, Furrer D, Laperriere D, Tahir M, Mader S, Diorio C Mod Pathol. 2017; 30(5):682-697.

PMID: 28084344 DOI: 10.1038/modpathol.2016.231.


MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder.

Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J Mol Med Rep. 2016; 14(5):4581-4592.

PMID: 27748889 PMC: 5102005. DOI: 10.3892/mmr.2016.5851.


Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a.

Liu F, Yuan J, Huang J, Yang F, Wang T, Ma J Oncogene. 2016; 35(41):5422-5434.

PMID: 27065331 DOI: 10.1038/onc.2016.80.